[go: up one dir, main page]

DK4269444T5 - Multispecifikke antistoffer mod variabel anti-tcr-delta 1 - Google Patents

Multispecifikke antistoffer mod variabel anti-tcr-delta 1 Download PDF

Info

Publication number
DK4269444T5
DK4269444T5 DK23187269.8T DK23187269T DK4269444T5 DK 4269444 T5 DK4269444 T5 DK 4269444T5 DK 23187269 T DK23187269 T DK 23187269T DK 4269444 T5 DK4269444 T5 DK 4269444T5
Authority
DK
Denmark
Prior art keywords
tcr
delta
antibodies against
multispecific antibodies
variable anti
Prior art date
Application number
DK23187269.8T
Other languages
English (en)
Other versions
DK4269444T3 (en
Inventor
Mark Uden
Mihriban Tuna
Natalie Mount
Robert Good
Joshua Freedman
Shefali Bhumbra
Oliver Nussbaumer
Raj Jaysukhlal Mehta
Original Assignee
Gammadelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4269444(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en
Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en
Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en
Application filed by Gammadelta Therapeutics Ltd filed Critical Gammadelta Therapeutics Ltd
Application granted granted Critical
Publication of DK4269444T3 publication Critical patent/DK4269444T3/da
Publication of DK4269444T5 publication Critical patent/DK4269444T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
DK23187269.8T 2020-08-14 2021-08-14 Multispecifikke antistoffer mod variabel anti-tcr-delta 1 DK4269444T5 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en) 2021-02-17 2021-02-17 Anti-TRC delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en) 2021-02-17 2021-02-17 Multispecific anti-TCR delta variable 1 antibodies
EP23153152.6A EP4218932A3 (en) 2020-08-14 2021-08-14 Multispecific anti-tcr delta variable 1 antibodies

Publications (2)

Publication Number Publication Date
DK4269444T3 DK4269444T3 (en) 2024-08-19
DK4269444T5 true DK4269444T5 (da) 2024-08-26

Family

ID=80247426

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21756070.5T DK4010082T5 (da) 2020-08-14 2021-08-14 Multispecifikke antistoffer mod variabel anti-tcr-delta 1
DK23187269.8T DK4269444T5 (da) 2020-08-14 2021-08-14 Multispecifikke antistoffer mod variabel anti-tcr-delta 1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK21756070.5T DK4010082T5 (da) 2020-08-14 2021-08-14 Multispecifikke antistoffer mod variabel anti-tcr-delta 1

Country Status (18)

Country Link
EP (7) EP4265642B1 (da)
JP (1) JP2023537534A (da)
KR (1) KR20230083267A (da)
CN (1) CN116209456A (da)
AU (1) AU2021323512A1 (da)
BR (1) BR112023002741A2 (da)
CA (1) CA3188682A1 (da)
CO (1) CO2023003009A2 (da)
DK (2) DK4010082T5 (da)
ES (2) ES2943063T3 (da)
FI (2) FI4269444T3 (da)
IL (1) IL300517A (da)
LT (2) LT4010082T (da)
MX (1) MX2023001728A (da)
PL (2) PL4269444T3 (da)
PT (2) PT4010082T (da)
SI (2) SI4269444T1 (da)
WO (1) WO2022034562A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4265642B1 (en) 2020-08-14 2024-06-26 GammaDelta Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
CA3259326A1 (en) * 2022-06-23 2023-12-28 LAVA Therapeutics N.V. T-LYMPHOCYTE-DEPENDENT MULTISPECIFIC COMPOUND ACTIVITY TEST
WO2024193459A1 (en) * 2023-03-17 2024-09-26 Nanjing Legend Biotech Co., Ltd. METHODS OF CULTURING Vδ1 T CELLS
WO2025147597A1 (en) * 2024-01-05 2025-07-10 Eugit Therapeutics, Inc. Targeting payloads
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
WO2015063069A1 (en) * 2013-10-28 2015-05-07 Benjamin Felder Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
CN114958738A (zh) 2015-06-09 2022-08-30 淋巴-淋巴细胞活化技术公司 用于生产TCRγδ+T细胞的方法
US10946095B2 (en) * 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
WO2017072367A1 (en) 2015-10-30 2017-05-04 Cancer Research Technology Limited EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS
KR102519861B1 (ko) 2016-05-12 2023-04-10 아디셋 바이오, 인크. γδ T-세포 집단의 선택적 확장을 위한 방법 및 그의 조성물
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CA3032304A1 (en) 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
CN111148761B (zh) 2017-06-25 2024-02-13 西雅图免疫公司 多特异性抗体及其制备和使用方法
US10519236B2 (en) 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
WO2020060405A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
AU2020212563A1 (en) * 2019-01-23 2021-09-16 New York University Antibodies specific to delta 1 chain of T cell receptor
CN113993893A (zh) * 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
CA3136251A1 (en) 2019-04-08 2020-10-15 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
JP7764364B2 (ja) 2019-08-16 2025-11-05 ガンマデルタ セラピューティクス リミティッド エクスビボγδ Ｔ細胞集団
WO2021032960A1 (en) * 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Novel anti-tcr delta variable 1 antibodies
EP4265642B1 (en) 2020-08-14 2024-06-26 GammaDelta Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
MX2023009360A (es) 2021-02-17 2023-09-21 Gammadelta Therapeutics Ltd Anticuerpos anti- variable delta 1 de tcr.

Also Published As

Publication number Publication date
KR20230083267A (ko) 2023-06-09
EP4269444A2 (en) 2023-11-01
MX2023001728A (es) 2023-04-20
PL4010082T3 (pl) 2023-05-29
EP4010082B1 (en) 2023-01-25
EP4218932A3 (en) 2023-09-27
EP4265643A2 (en) 2023-10-25
DK4269444T3 (en) 2024-08-19
SI4010082T1 (sl) 2023-04-28
JP2023537534A (ja) 2023-09-01
ES2993071T3 (en) 2024-12-20
FI4010082T3 (fi) 2023-04-04
EP4269446B1 (en) 2024-06-26
FI4269444T3 (fi) 2024-09-20
EP4269445A2 (en) 2023-11-01
ES2943063T3 (es) 2023-06-08
EP4265643B1 (en) 2024-06-26
EP4269444A3 (en) 2024-02-14
IL300517A (en) 2023-04-01
EP4010082A1 (en) 2022-06-15
PT4010082T (pt) 2023-04-26
WO2022034562A1 (en) 2022-02-17
EP4265642B1 (en) 2024-06-26
DK4010082T5 (da) 2024-08-05
CN116209456A (zh) 2023-06-02
EP4218932A2 (en) 2023-08-02
LT4269444T (lt) 2024-09-25
EP4265642A3 (en) 2024-02-14
EP4269445B1 (en) 2024-06-26
BR112023002741A2 (pt) 2023-10-10
EP4269446A3 (en) 2024-02-14
SI4269444T1 (sl) 2024-10-30
EP4269446A2 (en) 2023-11-01
CA3188682A1 (en) 2022-02-17
EP4265642A2 (en) 2023-10-25
EP4269444B1 (en) 2024-06-26
LT4010082T (lt) 2023-03-10
DK4010082T3 (da) 2023-04-03
EP4265643A3 (en) 2024-02-14
PL4269444T3 (pl) 2025-01-13
PT4269444T (pt) 2024-09-05
CO2023003009A2 (es) 2023-03-17
AU2021323512A1 (en) 2023-04-13
EP4269445A3 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
DK3872091T3 (da) Antistoffer mod sars-cov-2
DK4269444T5 (da) Multispecifikke antistoffer mod variabel anti-tcr-delta 1
DK4165024T3 (da) Cyclobutyldihydroquinolinsulfonamid-forbindelser
CR20230573A (es) ANTICUERPOS ANTI-SIRP-alfa
DK4320112T3 (da) Pyridinylsubstituerede oxoisoindolinforbindelser
DK4214240T3 (da) Anti-ccr8-antistoffer
EP4239011A4 (en) Polyamide
IL310528A (en) Pyrazolopyridinone compounds
DK3946179T4 (da) Stomiposer
EP4163107A4 (en) Decorative sheet
EP4392455A4 (en) ANTI-CD-25 ANTIBODIES
IL310245A (en) Anti-hla-g antibodies
EP4300176A4 (en) DECORATIVE FILM
UA45074S (uk) 1. навушники
EP4455214A4 (en) POLYAMIDE COMPOSITION
EP4455217A4 (en) POLYAMIDE COMPOSITION
EP4455218A4 (en) POLYAMIDE COMPOSITION
IL311043A (en) Anti-il-11rα antibodies
EP3966284A4 (en) POLYAMIDE COMPOSITION
JP1746772S (ja) 引き出し内オーガナイザー
IL309352A (en) Improved film
EP4311082A4 (en) COMPONENT
EP4098693A4 (en) POLYAMIDE COMPOSITION
DK4172199T3 (da) Alfa-synuklein-protofibril-bindende antistoffer
EP4399932C0 (en) OVERLAYED TRANSMISSIONS ORCHESTRATED BY AP